Article

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant

2021-05-14

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Covid-19 vaccines are urgently needed, especially against emerging variants. NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 rS) nanoparticle vaccine containing trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant. <h4>Methods</h4> A phase 3, randomized, observer-blinded, placebo-controlled trial was conducted in adu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3003ddc5-3f10-59e1-804e-1f399f828392
DOI: 10.1101/2021.05.13.21256639

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 VariantDOI 10.1101/2021.05.13.21256639Read

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 VariantSemantic proximity Read

Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled StudySemantic proximity Read

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineSemantic proximity Read

Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adultsSemantic proximity Read

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and MexicoSemantic proximity Read

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: a phase 3, randomized, placebo-controlled trial (PREVENT-19)Semantic proximity Read

Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trialSemantic proximity Read

Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 TrialSemantic proximity Read

NVX-CoV2373 Vaccine Efficacy Against Hospitalization: A<i>post hoc</i>analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trialSemantic proximity Read

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trialSemantic proximity Read

<strong>Efficacy of COVID-19 Vaccines Against the Omicron Variant of SARS-CoV-2</strong>Semantic proximity Read

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled TrialSemantic proximity Read